Conditions:  Recurrent Ovarian Cancer;  Recurrent Epithelial Cancer of Ovary;  Recurrent Epithelial Ovarian Cancer;  Recurrent Fallopian Tube Cancer;  Peritoneal Cancer;  Recurrent Carcinoma of Ovary;  Adenocarcinoma of Ovary
Interventions: Â Biological:Â Oregovomab; Â Drug:Â Niraparib
Sponsors:  OncoQuest Pharmaceuticals Inc.;  Veristat, LLC
**RECRUITING NOW**
Interventions: Â Biological:Â Oregovomab; Â Drug:Â Niraparib
Sponsors:  OncoQuest Pharmaceuticals Inc.;  Veristat, LLC
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
